The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Nanoparticles in Targeted Cancer Therapy: Mesoporous Silica Nanoparticles Entering Preclinical Development Stage
Abstract
Nanotechnology may help overcome persisting limitations of current cancer treatment and thus contribute to the creation of more effective, safer and more affordable therapies. While some nanotechnology-based drug delivery systems are already being marketed and others are in clinical trial, most still remain in the preclinical development stage. Mesoporous silica nanoparticles have been highlighted as an interesting drug delivery platform, due to their flexibility and high drug load potential. Although numerous reports demonstrate sophisticated drug delivery mechanisms in vitro, the therapeutic benefit of these systems for in vivo applications have been under continuous debate. This has been due to nontranslatable conditions used in the in vitro studies, as well as contradictory conclusions drawn from preclinical (in vivo) studies. However, recent studies have indicated that the encouraging cellular studies could in fact be repeated also in vivo. Here, we report on these recent advances regarding therapeutic efficacy, targeting and safety issues related to the application of mesoporous silica nanoparticles in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Nanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J., Wang, A., Langer, R., & Farokhzad, O. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,657
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Kim, J., Kim, H. S., Lee, N., Kim, T., Kim, H., Yu, T., Song, I. C., Moon, W. K., & Hyeon, T. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200802469 · Cited by 1,220
Lu, J., Liong, M., Li, Z., Zink, J. I., & Tamanoi, F. (2010) · Small · doi:10.1002/smll.201000538 · Cited by 1,074
Mesoporous Silica Nanoparticles for Intracellular Controlled Drug Delivery
Vivero‐Escoto, J. L., Slowing, I. I., Trewyn, B. G., & Lin, V. S. ‐. (2010) · Small · doi:10.1002/smll.200901789 · Cited by 998
Bright and Stable Core−Shell Fluorescent Silica Nanoparticles
Ow, H., Larson, D. R., Srivastava, M., Baird, B. A., Webb, W. W., & Wiesner, U. (2005) · Nano Letters · doi:10.1021/nl0482478 · Cited by 932
Huang, X., Li, L., Liu, T., Hao, N., Liu, H., Chen, D., & Tang, F. (2011) · ACS Nano · doi:10.1021/nn200365a · Cited by 921
Lin, Y.-S., & Haynes, C. L. (2010) · Journal of the American Chemical Society · doi:10.1021/ja910846q · Cited by 837
Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
Libutti, S. K., Paciotti, G. F., Byrnes, A. A., Alexander, H. R., Gannon, W. E., Walker, M., Seidel, G. D., Yuldasheva, N., & Tamarkin, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0978 · Cited by 710
Cited by
Multifunctional Mesoporous Silica Nanoparticles as a Universal Platform for Drug Delivery
Argyo, C., Weiss, V., Bräuchle, C., & Bein, T. (2014) · Chemistry of Materials · doi:10.1021/cm402592t · Cited by 903
Croissant, J. G., Fatieiev, Y., & Khashab, N. M. (2017) · Advanced Materials · doi:10.1002/adma.201604634 · Cited by 782
Chen, Y., Chen, H., & Shi, J. (2013) · Advanced Materials · doi:10.1002/adma.201205292 · Cited by 724
Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe
Phillips, E., Penate-Medina, O., Zanzonico, P. B., Carvajal, R. D., Mohan, P., Ye, Y., Humm, J., Gönen, M., Kalaigian, H., Schöder, H., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009524 · Cited by 712
Croissant, J. G., Fatieiev, Y., Almalik, A., & Khashab, N. M. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700831 · Cited by 594
Mesoporous silica nanoparticles for therapeutic/diagnostic applications
Jafari, S., Derakhshankhah, H., Alaei, L., Fattahi, A., Varnamkhasti, B. S., & Saboury, A. A. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.167 · Cited by 566
Mesoporous Silica Nanoparticles for Drug Delivery: Current Insights
Vallet-Regí, M., Colilla, M., Izquierdo-Barba, I., & Manzano, M. (2017) · Molecules · doi:10.3390/molecules23010047 · Cited by 538
Cheng, W., Nie, J., Xu, L., Liang, C., Peng, Y., Liu, G., Wang, T., Mei, L., Huang, L., & Zeng, X. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b02457 · Cited by 461
Chen, Y., Meng, Q., Wu, M., Wang, S., Xu, P., Chen, H., Li, Y., Zhang, L., Wang, L., & Shi, J. (2014) · Journal of the American Chemical Society · doi:10.1021/ja508721y · Cited by 374
Chen, Y., & Shi, J. (2016) · Advanced Materials · doi:10.1002/adma.201505147 · Cited by 356
Yu, L., Chen, Y., Wu, M., Cai, X., Yao, H., Zhang, L., Chen, H., & Shi, J. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b04299 · Cited by 305
Du, X., Li, X., Xiong, L., Zhang, X., Kleitz, F., & Qiao, S. Z. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.019 · Cited by 262
Kuthati, Y., Kankala, R. K., & Lee, C.-H. (2015) · Applied Clay Science · doi:10.1016/j.clay.2015.04.018 · Cited by 258
Tumor-targeted biodegradable multifunctional nanoparticles for cancer theranostics
Yang, S., Chen, L., Zhou, X., Sun, P., Fu, L., You, Y., Xu, M., You, Z., Kai, G., & He, C. (2019) · Chemical Engineering Journal · doi:10.1016/j.cej.2019.122171 · Cited by 35
Metadata
- Authors
- Rosenholm, J. M., Mamaeva, V., Sahlgren, C., & Lindén, M.
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2011-12-22
- Volume
- 7
- Issue
- 1
- Pages
- 111-120
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W1982426647
- Cited by
- 263
- References
- 53
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.